The Role of CGRP-targeted Therapies in the Management of Migraine: Examining Opportunities for Pharmacist Intervention

Program Description
Migraines can present with acute or chronic symptoms and can significantly impact a person’s quality of life, with some individuals experiencing more than 15 migraine days per month. Often, migraine headaches are accompanied by other symptoms such as nausea and/or vomiting, photophobia, or aura. While many people experiencing migraine seek pharmacologic management, overall rates of preventive prescription medications remains low, and a large proportion of patients treated with prescription medications either switch or discontinue treatment. Research on the role of calcitonin gene-related peptide (CGRP) in migraine has led to many advancements in recent years with new FDA-approved therapies for the treatment and prevention of migraines. To promote adequate management of migraine and improve quality of life for patients, pharmacists need to be familiar with these emerging classes of medications as well as guideline-recommended therapies and monitoring treatment plans for migraine. This activity will detail the importance of providing patient-centered care and review opportunities for pharmacists to assist with appropriate pharmacologic management of patients with migraine.

Target Audience: Retail pharmacists

Type of Activity: Application
Release date: December 23, 2021
Expiration date: December 23, 2022
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the epidemiology, pathophysiology, clinical presentation, and health-related quality of life for patients with migraine

• Analyze emerging therapies including recently approved medications for the management of migraine including mechanism of action, administration, the latest data on efficacy and safety, and guideline recommendations

• Illustrate the role of the pharmacist in improving the care of patients with migraine through interventions related to patient identification, medication use, and patient education

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-21-458-H01-P. The activity is available for CE credit through December 23, 2022.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, read the article in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Chris Herndon, PharmD, BCACP, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Liza Patel, PharmD, RPh; Liz Rauh; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms